Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808757 | 1.00 | TSHR (0.46) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL26077510 | 0.85 | TSHR (0.41) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL29738282 | 0.80 | AAK1 (0.41) | MAPK1ALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL482094 | 0.80 | AAK1 (0.41) | MAPK1ALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL57316 | 0.80 | TSHR (0.48) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL29467181 | 0.80 | TSHR (0.48) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| Ammonia Solution, Strong SCHEMBL28172715 | 0.78 | AAK1 (0.41) | MAPK1ALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL1588832 | 0.77 | ALDH1A1 (0.49) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL12391630 | 0.77 | TSHR (0.46) | TSHRMAPK1ALDH1A1CYP3A4TDP1 | |
| SCHEMBL29563051 | 0.77 | ALDH1A1 (0.49) | TSHRMAPK1ALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORP (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023250430-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| CN-101384593-A | 3-deazapurine derivatives as tlr7 modulators | PFIZER LTD (GB) | 2009-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TSHR 4485/4885MAPK1 377/4885ALDH1A1 2211/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | TSHR 4485/4885MAPK1 377/4885ALDH1A1 2211/4885 |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | TSHR 3466/4885MAPK1 772/4885ALDH1A1 4341/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | TSHR 2364/4885MAPK1 538/4885ALDH1A1 2596/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | TSHR 4485/4885MAPK1 377/4885ALDH1A1 2211/4885 |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | TSHR 3184/4885MAPK1 363/4885ALDH1A1 1459/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TSHR 4451/4885MAPK1 381/4885ALDH1A1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.